09:12 AM EDT, 09/30/2025 (MT Newswires) -- Vaxcyte ( PCVX ) said Tuesday that Thermo Fisher Scientific ( TMO ) will provide custom commercial fill-finish capacity for Vaxcyte's ( PCVX ) broad-spectrum pneumococcal conjugate vaccines at its North Carolina facility.

The company said its new agreement with Thermo Fisher is a "key element" of its long-term commercial supply strategy in the US.

Vaxcyte ( PCVX ) said the initiative includes manufacturing and related services and represents up to $1 billion in manufacturing commitment for the company.

Vaxcyte ( PCVX ) shares were up over 2% while Thermo Fisher shares were relatively flat in recent premarket activity.